<DOC>
	<DOCNO>NCT00083187</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , VNP40101M hydroxyurea , work different way stop cancer cell divide stop grow die . Hydroxyurea may help VNP40101M kill cancer cell make cancer cell sensitive drug . PURPOSE : This phase II trial study well give VNP40101M hydroxyurea work treat patient acute myelogenous leukemia high-risk myelodysplasia .</brief_summary>
	<brief_title>VNP40101M Treating Patients With Acute Myelogenous Leukemia High-Risk Myelodysplasia</brief_title>
	<detailed_description>OBJECTIVES : - Determine complete response rate VNP40101M patient acute myelogenous leukemia high-risk myelodysplasia . - Determine toxic effect regimen patient . - Determine pharmacokinetics regimen patient . OUTLINE : This open-label , multicenter study . Patients stratify acute myelogenous leukemia ( AML ) high risk myelodysplasia ( MDS ) patient ≥ 60 year old prior treatment v AML patient age first relapse . ( AML patient age first relapse close accrual 06/09/05 ) . Patients receive VNP40101M IV 30 minute day 1 ( course 1 ) . Four five week first course , patient undergo bone marrow aspiration biopsy . If bone marrow improve contains residual leukemia , patient receive second course VNP40101M ( dose course 1 ) . If patient achieve complete response ( CR ) , partial CR first second course , consolidation course may give comprise VNP40101M reduce dose . Patients follow monthly 6 month , every 2 month 12 month , every 3 month 18 month . PROJECTED ACCRUAL : A total 230 patient ( 100 acute myelogenous leukemia ( AML ) high-risk myelodysplasia 130 AML first relapse ) accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 following : Acute myelogenous leukemia ( AML ) , meet follow criterion : In first relapse first treatmentinduced complete remission ( CR ) ( close accrual 06/09/05 ) Duration first CR le 12 month No prior treatment first relapse except hydroxyurea FAB type M0 , M1 , M2 , M47 No acute promyelocytic leukemia No prior treatment standard induction regimen contain cytotoxic agents* ( patient 60 year age old ) Highrisk myelodysplasia , meet follow criterion : 60 year age No prior cytotoxic chemotherapy* except hydroxyurea Prior gemtuzumab ozogamicin allow High risk define International Prognostic Scoring System score ≥ 1.5 , define cytogenetics , % marrow blast , lineage cytopenias NOTE : *Prior lowdose , singleagent cytarabine , decitabine , azacitidine consider prior cytotoxic chemotherapy PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Not specify Hepatic Bilirubin ≤ 2.0 mg/dL ALT AST ≤ 5 time upper limit normal Chronic hepatitis allow Renal Creatinine ≤ 2.0 mg/dL Cardiovascular No myocardial infarction within past 3 month No symptomatic coronary artery disease No uncontrolled arrhythmias No uncontrolled congestive heart failure No active heart disease Other No uncontrolled active infection Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Up 4 leukapheresis procedure allow first 15 day study treatment Chemotherapy See Disease Characteristics Concurrent additional hydroxyurea ( maximum dose 5 g daily 4 day ) allow day 4 15 study course control elevate blast level Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other Recovered prior therapy At least 72 hour since prior antileukemic treatment noncytotoxic agent No concurrent disulfiram ( Antabuse ) No concurrent anticancer drug except anagrelide within first 15 day study treatment control elevate platelet count No concurrent treatment leukemia , except hydroxyurea use study treatment No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>